Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples

Margaret A. Black, Guomiao Shen, Xiaojun Feng, Wilfredo F. Garcia Beltran, Yang Feng, Varshini Vasudevaraja, Douglas Allison, Lawrence H. Lin, Tatyana Gindin, Michael Astudillo, Diane Yang, Mandakolathur Murali, A. John Iafrate, George Jour, Paolo Cotzia, Matija Snuderl

TL;DR

Researchers validated a rapid lateral flow immunoassay (LFI) for SARS-CoV-2, demonstrating that finger-stick capillary blood provides diagnostic sensitivity (93%) comparable to traditional venous blood draws. The study confirms that while these rapid tests are highly effective seven days after a positive PCR result, their performance is strongly time-dependent, highlighting their role in screening past exposure rather than acute infection.

What Problem Does This Paper Address?

During the early stages of the COVID-19 pandemic, RT-PCR was the gold standard for diagnosing active infections. However, PCR requires specialized labs, invasive nasopharyngeal swabs, and doesn't indicate if someone was previously infected and has since recovered.

Serological tests (antibody tests) fill this gap by identifying past exposure and potential immunity. While Enzyme-Linked Immunosorbent Assays (ELISA) are the laboratory "gold standard" for antibodies, they are slow and require trained technicians. Lateral flow immunoassays (LFIs)—similar to home pregnancy tests—offer a rapid, decentralized alternative. The challenge addressed here is the lack of rigorous validation for these LFIs, particularly regarding whether they can reliably use a simple finger-stick (capillary blood) instead of a professional venous blood draw.

Methods

The authors conducted a retrospective validation of the Biolidics 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold). They compared its performance against an in-house ELISA developed by MGH/Ragon.

Key aspects of the methodology included:

  • Matrix Comparison: Testing the LFI across four sample types: serum, plasma, venous whole blood, and capillary finger-stick blood.
  • Temporal Analysis: Evaluating sensitivity at "Day 0" (the day of a positive PCR result) versus "Day 7" (seven or more days later).
  • Independent Verification: Each LFI test was read by two independent observers to minimize subjective bias.

Datasets

The study utilized samples from 62 patients at NYU Langone Medical Center:

  • Positive Cohort: 39 patients confirmed positive for SARS-CoV-2 via RT-qPCR.
  • Negative Control Cohort: 24 patients, including 20 archived plasma samples from early 2019 (pre-COVID era) to test for cross-reactivity and 4 samples from March 2020 from PCR-negative patients.
  • Capillary Cohort: 14 patients who had recovered from COVID-19 (18–46 days post-diagnosis) specifically for finger-stick validation.

Key Insights and Ideas

  • The "Wait Period" is Critical: Sensitivity jumped from a meager 29% on the day of PCR diagnosis to 92% just one week later. This underscores that LFIs are "exposure" tests, not "infection" tests; the body needs time to mount a detectable antibody response.
  • IgG is More Reliable than IgM: The test achieved 100% specificity for IgG, whereas IgM had a 92% specificity (showing some false positives in pre-COVID samples). This suggests IgG is the more dependable marker for confirming prior exposure.
  • Finger-Sticks are Viable: One of the most significant findings was that capillary blood from a finger-stick performed as well as venous blood. This validates the potential for decentralized, point-of-care, or even self-testing.
  • LFI as a Proxy for High Titers: The researchers found that a positive LFI result strongly correlated with high antibody concentrations in ELISA, suggesting the rapid test can effectively identify individuals with robust immune responses.

Key Results

  • Overall Sensitivity: 92% at ≥7 days post-PCR diagnosis for venous blood.
  • Capillary Sensitivity: 93% for antibody detection using finger-stick samples in recovered patients.
  • Specificity: 100% for IgG and 92% for IgM.
  • Statistical Concordance: There was no significant difference between LFI and ELISA performance at Day 0 or Day 7 (p=1.00), with the minor exception of IgM detection at Day 7.
  • Reproducibility: Results were consistent across plasma and whole blood, meaning labs can skip the time-consuming step of centrifuge-separating plasma for these tests.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The cohort for capillary blood validation was relatively small (14 patients).
  • Immunity vs. Exposure: While the test detects antibodies, the authors stress that the presence of antibodies does not yet strictly guarantee protective immunity against re-infection.
  • Inter-individual Variability: The study noted cases where household members with similar symptoms had vastly different antibody kinetics, suggesting a need for larger longitudinal studies to understand how long antibody production lasts.
  • Subjectivity: LFI results rely on visual interpretation of faint bands; the authors suggest that using AI or image-analysis software could further reduce human error in future applications.

Summary updated

Abstract

<p>Objectives: We validate the use of a lateral flow immunoassay (LFI) intended for rapid screening and qualitative detection of anti-SARS-CoV-2 IgM and IgG in serum, plasma, and whole blood, and compare results with ELISA. We also seek to establish the value of LFI testing on blood obtained from a capillary blood sample. Methods: Samples collected by venous blood draw and finger stick were obtained from patients with SARS-CoV-2 detected by RT-qPCR and control patients. Samples were tested with Biolidics 2019-nCoV IgG/IgM Detection Kit lateral flow immunoassay, and antibody calls were compared with ELISA. Results: Biolidics LFI showed clinical sensitivity of 92% with venous blood at 7 days after PCR diagnosis of SARS-CoV-2. Test specificity was 92% for IgM and 100% for IgG. There was no significant difference in detecting IgM and IgG with Biolidics LFI and ELISA at D0 and D7 (p = 1.00), except for detection of IgM at D7 (p = 0.04). Capillary blood of SARS-CoV-2 patients showed 93% sensitivity for antibody detection. Conclusions: Clinical performance of Biolidics 2019-nCoV IgG/IgM Detection Kit is comparable to ELISA and was consistent across sample types. This provides an opportunity for decentralized rapid testing and may allow point-of-care and longitudinal self-testing for the presence of anti-SARS-CoV-2 antibodies.</p>
BibTeX
@article{black2021analytical,
  author = {Margaret A. Black and Guomiao Shen and Xiaojun Feng and Wilfredo F. Garcia Beltran and Yang Feng and Varshini Vasudevaraja and Douglas Allison and Lawrence H. Lin and Tatyana Gindin and Michael Astudillo and Diane Yang and Mandakolathur Murali and A. John Iafrate and George Jour and Paolo Cotzia and Matija Snuderl},
  title = {{Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples}},
  journal = {Journal of Immunological Methods},
  year = {2021},
  url = {https://openreview.net/forum?id=6WOlMAPe85},
}

Loading related content...

Figure